Explicyte Immuno-Oncology

What do we do at Explicyte Immuno-Oncology? Alban Bessede, PhD, founder and CEO of Explicyte, provides a quick overview in 90 seconds. #Preclinical #Translational #Research #Cancer #Immunotherapy #CRO

#NewPaper in Cell Reports Medicine by Cell Press: A 25-Gene Signature of T Cell Exhaustion Predicts Immunotherapy Response in Lung Adenocarcinoma Full text: https://lnkd.in/dSx-K2zc This retrospective work, led by Prof. Italiano Antoine (Institut Bergonié Comprehensive Cancer Center) and funded by AstraZeneca and the Région Nouvelle-Aquitaine, is based on the BIP study (NCT02534649). It seeks to evaluate the #predictive value of CD8+ #Tcell #exhaustion in #LungAdenocarcinoma patients treated with #ImmuneCheckpointInhibitors. #Multiplex #Immunohistofluoresence (mIHF): We analyzed tumor samples from 166 patients with advanced lung adenocarcinoma, collected before their treatment with anti-PD1/PD-L1 immunotherapy with a panel indicative of tumor-infiltrating lymphocyte (TIL) exhaustion (CD8, CK7, LAG3, PD1, TIGIT, and TIM3). Non-responders featured a high proportion of CD8+ T cells co-expressing PD1 and at least one other marker of exhaustion (LAG3, TIGIT, or TIM3). This profile was associated with poorer clinical outcomes, independently of other factors such as age, gender, and PD-L1 status assessed by IHC. #WholeTranscriptome Analysis:  We then analyzed a total of 135 FFPE samples - characterized for their exhaustion status by mIHF - using the HTG transcriptome panel (19,000+ targets). From this analysis, we identified a 25-gene transcriptomic signature strongly associated with the exhaustion phenotype, demonstrating high predictive accuracy. #Validation on #ExternalDatasets, beyond #LungCancer: The robustness of this signature was validated in external datasets from NSCLC clinical trials (POPLAR [NCT02517892], OAK [NCT0200822], and MATCH-R [NCT02517892]). Datasets from the CA209-038 melanoma trial (NCT01621490) and the JAVELIN Renal 101 (NCT0268400601) trial in renal carcinoma further confirmed the #robustness of the #CD8+ #TCellExhaustion #Signature as a #Biomarker for #Stratifying #Patients likely to benefit from #Immunotherapy. Thanks to all contributors! Jean-Philippe Guégan, Florent Peyraud, Bérengère Dadone-Montaudie, Diego Teyssonneau, Lola-Jade Palmieri, Emma Clot, Sophie Cousin, Guilhem Roubaud, Mathilde Cabart, Laura Roy, Coriolan Lebreton, Christophe REY, Oren Lara, Ophélie Odin, Maxime Brunet, Lucile Vanhersecke, Ezogelin Oflazoglu-Gruyters, Ikbel Achour, Leila Belcaid, Sylvestre Le Moulec, Thomas GRELLETY, Alban Bessede, PhD, Italiano Antoine, Centre Hospitalier Universitaire de Nice (CHU de Nice), University of Copenhagen (Københavns Universitet), Clinique Marzet, CENTRE HOSPITALIER DE LA COTE BASQUE Learn more about Explicyte Immuno-Oncology's services in translational research: https://lnkd.in/daWg_DcS

We're hiring a #DataScientist in #ImmunoOncology in Bordeaux! You like to play with large multi-omics datasets and analyze spatial information? You have an interest in the biological processes involved in the response to cancer immunotherapies ? Apply: https://lnkd.in/d7TiAS6G

Enthusiastic feedback from our CSO, Imane Nafia, about the #SITC2024 cancer immunotherapy meeting in Houston!

#NewPaper in the Journal of Hematology & Oncology! Full text: https://lnkd.in/dRY3Jt-K In this retrospective study led by Prof. Italiano Antoine (Institut Bergonié & Gustave Roussy Comprehensive Cancer Centers) based on the NEOSARCOMICS trial, we investigated whether #microenvironment features of #UndifferentiatedPleomorphicSarcomas (UPS) – an aggressive subtype of soft tissue sarcoma – could predict response to #neoadjuvant anthracycline-based #chemotherapy. #MicroenvironmentFeatures & prognosis without #NeoadjuvantTherapy:  We applied a multiplexed immunohistofluorescence (mIHF) panel on tumor samples from 47 patients with UPS who underwent surgical resection. We found that patients with poor survival had fewer infiltrated immune cells (especially CD8+ cells and M1 macrophages), while patients with better overall survival tended to feature high tumor infiltration. #MicroenvironmentFeatures & #response to #NeoadjuvantTherapy:  We then analyzed the gene expression of baseline samples from 24 patients with resectable UPS, who were treated with neoadjuvant chemotherapy. We found that a good response was associated with a high proliferation and low immune infiltration phenotype. This finding was confirmed with the multiplex mIHF panel: patients who poorly respond to neoadjuvant therapy feature high immune infiltration. #PlasmaProteomics confirmed the upregulation of cell cycle pathways in low immune infiltration patients. These results suggest that immune infiltration status can serve to stratify UPS patients before surgical resection. Patients with high immune infiltration benefit from a better prognosis from the start and may respond poorly to chemotherapy. However, neoadjuvant therapy may improve the prognosis of immune-low UPS patients. Thanks to all contributors! Jean-Philippe Guégan, Nathan El Ghazzi, Julien Vibert (李满山), Christophe REY, Lucile Vanhersecke, Jean Michel Coindre, Maud Toulmonde, Mariella SPALATO CERUSO, Florent Peyraud, Alban Bessede, PhD, Italiano Antoine, Université de Bordeaux, CHU de Clermont-Ferrand. Learn more about Explicyte Immuno-Oncology's services in translational research: https://lnkd.in/daWg_DcS

Explicyte is the⚡first #ImmunoOncology #CRO in #Europe⚡equipped with 10x Genomics #Xenium platform for #SingleCell #SpatialTranscriptomics! Training by the 10x team started! Why is it exciting? Alban Bessede, PhD, CEO of Explicyte Immuno-Oncology: “For our translational and data science team, the Xenium platform opens unexplored avenues for analyzing tumors and their microenvironment in response to various cancer modalities, including immunotherapies. For our sponsors, gaining a deep understanding of the gene expression profiles and spatial distribution of individual cells within a tumor specimen can provide unique insights into tumor biology and the mechanisms at play in anti-cancer response or resistance to treatment. It creates opportunities to identify new therapeutic targets and predictive biomarkers for cancer patients. And as a scientist, I’m eager to watch tumor cells, immune cells, and cancer-associated fibroblasts with the Xenium eye, and to witness the single-cell architecture of immune infiltrates and tertiary lymphoid structures. It’s truly exciting to enter the world of single-cell spatial transcriptomics."   About the 10x Xenium platform: > Compatible with standard tumor specimens (frozen & FFPE) > TME architecture is visualized at subcellular level with a 5000-gene panel > Single-cell analysis & segmentation with AI-driven algorithm 

#Sarcoma #Microenvironment #Immunotherapy I attended yesterday with colleagues from Explicyte Immuno-Oncology the 2nd Symposium of the RHU CONDOR programme in Bordeaux. Insightful talks and discussions with world-class experts in sarcoma immunotherapy: > Sandra D'Angelo, MSKCC > John Stagg, Univ. Montreal > Wolf Hervé Fridman, Centre de Recherche des Cordeliers > Alessandra Merlini, Univ. Turin > Stephen Hunt, MTR, MD, PhD, FSIR, UPenn > Lucile Vanhersecke, Institut Bergonié > Thibaut Brugat, DOMAIN Therapeutics > Halin Bareke, Institute for Health Research IdiPAZ-CNIO > Yann Rodriguez, Owkin > And more... Thanks Italiano Antoine for setting up this meeting ! Paul Marteau, Imane Nafia, Jean-Philippe Guégan, Loic Cerf

New Paper in #MolecularCancer! In this study led by Prof. Italiano Antoine (Institut Bergonié & Gustave Roussy Comprehensive Cancer Centers), 49 patients with advanced gastric cancer were treated with Avelumab (anti-PD/PD-L1) in combination with Regorafenib (anti-angiogenic drug). Despite encouraging efficacy results, a significant subset of patients did not respond. Explicyte Immuno-Oncology explored resistance mechanisms in specimens from the REGOMUNE & REGONIVO trials, using sequentially #SpatialTranscriptomics, #DigitalPathology, #PlasmaProteomics, highlighting that non-responding patients feature: > In the #ImmuneCompartment: CD163 gene overexpression, alongside an enrichment in M2 #macrophages (significant increase in M2/M1 ratio) > In #TumorCells: strong upregulation of S100A10 - a protein involved in macrophage chemotaxis > In #PlasmaSamples: Upregulation of cytokines involved in macrophage infiltration, such a CSF-1, IL-4, IL-8, and TWEAK. Altogether, this paper highlights the central role of #M2macrophages in the #resistance to anti-PD-1/PD-L1 #immunotherapy combined with #antiangiogenic therapy in gastric cancers, and provides perspectives for novel diagnostic and therapeutic approaches. Read paper: https://lnkd.in/dd2SSkqk Contributors : Sophie Cousin, Jean-Philippe Guégan, Kohei Shitara, Lola-Jade Palmieri, Jean-Philippe Metges, Simon Pernot, Shota Fukuoka, Shohei Koyama, Hiroyoshi Nishikawa, Carine Bellera, Antoine Adenis, Carlos Gomez-Roca, CASSIER Philippe, Antoine Hollebecque, Coralie Cantarel, Michèle Kind, Isabelle Soubeyran, Lucile Vanhersecke, Alban Bessede, PhD CHU de Brest, BPH Bordeaux Population Health - Centre de recherche sur la santé des populations de Bordeaux, IRCM - Institut de Recherche en Cancérologie de Montpellier, IUCT-Oncopole, Centre Léon Bérard, Olink Proteomics, NanoString Technologies, Inc., Akoya Biosciences, Inc.

#Hiring #PostDoc #Translational #Research #ImmunoOncology #Bordeaux #France Apply here: https://lnkd.in/dpbepdSb   🔬 What We’re Looking For: > Expertise in omics data analysis (transcriptomics: bulk, spatial, single-cell) > High proficiency in image analysis from multiplexed IHC/IHF > Ability to work autonomously and drive impactful research projects 📚 Your Mission: Make groundbreaking discoveries and contribute to high-impact scientific publications (check our past papers: https://lnkd.in/du-9cw76) If you’re ready to take on this challenge and make a difference in the fight against cancer, we’d love to hear from you! Learn more about Explicyte and apply: https://lnkd.in/dpbepdSb

LAST DAYS TO REGISTER! #Webinar #TLS #Modulation in #Cancer #Immunotherapy on Sept 5th. Don't miss out - register now: https://lnkd.in/dPg56QhY Talk #1 : Tertiary lymphoid structures as modulators of anti-tumor immunity: what do we know and where are we headed? by Tullia Bruno, PhD - UPMC Hillman Cancer Center / University of Pittsburgh Talk #2: Predictive role of TLS in cancer immunotherapy: Current insights and perspectives by Pr. Italiano Antoine, MD, PhD - Institut Bergonié & Gustave Roussy Comprehensive Cancer Centers This 45-minute webinar session will be hosted by Alban Bessede, PhD, CEO of Explicyte Immuno-Oncology. Learn more about Explicyte's in-house panels & expertise in TLS detection and evaluation for cancer immunotherapy: https://lnkd.in/dvuMa4-f